About HANSOH PHARMA Company

Our company is one of the leading pharmaceutical companies in China driven by R&D and innovation. With the mission of “continuous innovation to improve the quality of human life”, we are committed to becoming the world's leading innovation-driven pharmaceutical company. The company has established a leading position in some of the largest, fastest growing, and treatment fields with significant unmet medical needs in China, including anti-tumor, anti-infective, central nervous system diseases, metabolic and other diseases, and has successfully transformed into an innovative biopharmaceutical company focused on developing and selling innovative drugs. As of June 30, 2024, the Group has been approved for marketing a total of seven innovative drugs, all of which have been included in the national health insurance catalogue published by the National Health Insurance Administration. Revenue from innovative drugs and cooperative products is about RMB 5.32 billion, accounting for about 77.4% of revenue, and has become the core driving force for the sustainable growth of the company's performance.